Logo

Global Cancer Consortium: Cardio-Oncology Series - Shared screen with speaker view
Amit Arbune
31:53
Please post any questions in the chat and we will go over them at the end of the talk. Thank you. Amit Arbune
Vivek Rangnekar
53:02
Could you comment on the role of metformin in cardio-protection that goes beyond its hypoglycemic effects.
Mahadev Rao
53:11
Is cardiotoxicity in cancers may be due to drug interactions between cardiovascular drugs with anticancer drugs or immunotherapy drugs? Do you think pharmacogenomics screening for drug metabolizing enzymes before cancer therapy for these drugs may be helpful.?
Ananth Pai
01:00:52
how to monitor patients on immunotherapy for cardiac toxicity? like we monitor cardiac LV function for patients on anthracyclines or anti her 2 therapy which can cause LV dysfunction. are there any known biomarkers?
Marta Wood
01:01:27
Is medical cardioprotection warranted for cardiotoxicity due to radiation?
keerthanaa B
01:02:04
whether statins act as a risk factor in prostate/skin cancer?
Susan Yackzan
01:07:46
do you have any recommendations about risk assessment tools for use by oncology to help identify patients who may be at higher risk of cardiotoxicity?
Amit Arbune
01:11:46
https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.1920 - baseline CV risk assessment in pts scheduled to receive cardiotoxic therapies